Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $106 to $112.
Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $106 to $112.